BioMimetix Inc., founded in 2013 and based in Greenwood Village, Colorado, is a pioneering biopharmaceutical firm dedicated to developing innovative treatments for cancer patients. The company's core mission is to advance healthcare by creating compounds that mitigate radiation toxicity during cancer treatment. Their flagship product, BMX-001, is a redox-active metalloporphyrin designed to protect normal tissues from radiation damage while enhancing the effectiveness of cancer therapies.
Notable figures associated with BioMimetix include leading researchers and industry experts who have significantly contributed to the field of oncology. The company has garnered attention from key investors in the biopharmaceutical sector, supporting its groundbreaking work. BioMimetix's achievements include promising clinical trial results and numerous scientific publications, underscoring its potential to revolutionize cancer treatment and improve patient outcomes.
BioMimetix Pharmaceutical's most recent funding round was for $2M (USD) in July 2011.
As of Jul 26, 2011, BioMimetix Pharmaceutical has disclosed funding of $2M (USD).
RadioRx
radiorx.com

BioCurity Pharmaceuticals
biocurity.com

Endomimetics
endomimetics.com

Trevarx Biomedical
trevarx.com

Microbiotix
microbiotix.com
LipimetiX
lipimetix.com

CryptoMedix
cryptomedix.com

Metaphore Biotechnologies
metaphorebio.com

Sporos Bioventures

Molecular Templates
mtem.com

XTuit Pharmaceuticals
xtuit.com

Avetabiomics
avetabiomics.com

Manhattan BioSolutions

Intellimedix
intellimedix.com

Bond Biosciences
bond.bio

MaveriX Oncology

Meditope Biosciences
meditope.com

Bantam Pharmaceutical
bantampharma.com

MimiVax
mimivax.com

GlycoMimetics
glycomimetics.com

BioMimetix Inc., a Colorado-based biopharmaceutical firm, develops compounds for radiation toxicity treatment in cancer care.